CTIS2023-509419-10-00进行中（未招募）1 期
CFA-1034-1-23
aboratorios Cinfa S.A.0 个研究点目标入组 24 人开始时间: 2024年3月6日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Single dose, open-label, laboratory blinded, randomised, 2-treatment, 2-period, 2-sequence, crossover bioequivalence study of test product Perampanel 2 mg film-coated tablets versus reference product Fycompa 2 mg film-coated tablets (Eisai GmbH) in healthy adult male and female subjects under fasting conditions..A. (submitted trial is a bioequivalence study in healthy human subjects)MedDRA version: 20.0Level: HLGTClassification code: 10039911Term: Seizures (incl subtypes) Class: 10029205CTIS2023-504132-18-00aboratorios Cinfa S.A.36
进行中（未招募）
1 期
Conducting a quality study of the medicinal product - Vortioxetineo therapeutic indication in the current trial with healthy volunteers. The intended indication is for the treatment of major depressive episodes in adultsMedDRA version: 21.1Level: LLTClassification code: 10081270Term: Major depressive disorder Class: 10037175CTIS2023-509946-36-00CCDRD Cooperative Clinical Drug Research and Development AG36
招募中
1 期
FIPO23 Phase I/II, multi center, Open Label, First-in-human, Dose Escalation and Expansion study to investigate the Safety, Pharmacokinetics, and anti-tumors efficacy of the glyco-humanized polyclonal antibody XON7 in patients with advanced or metastatic solid tumors.CTIS2023-505266-29-00Xenothera246
招募中
1 期
Study on the investigational drug IAMA-6, placebo-controlled, administered to healthy adult volunteers, at single oral doses and at multiple ascending oral doses to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics of IAMA-6 and its interaction with foodCTIS2023-507454-33-00Iama Therapeutics S.r.l.72
进行中（未招募）
1 期
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative desigHealthy volunteersCTIS2023-504355-28-03Helsinn Healthcare S.A.74